ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

64.96USD+0.02 (+0.03%)Market Closed

Market Summary

USD64.96+0.02

Market Closed

0.03%

ALPN Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

ALPN Stock Price

View Fullscreen

ALPN RSI Chart

ALPN Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-120.97

Price/Sales (Trailing)

78.84

EV/EBITDA

-140.51

Price/Free Cashflow

-55.04

ALPN Price/Sales (Trailing)

ALPN Profitability

EBT Margin

-56.76%

Return on Equity

-11.07%

Return on Assets

-9.86%

Free Cashflow Yield

-1.82%

ALPN Fundamentals

ALPN Revenue

Revenue (TTM)

56.5M

Rev. Growth (Yr)

-25.09%

Rev. Growth (Qtr)

-77.21%

ALPN Earnings

Earnings (TTM)

-36.8M

Earnings Growth (Yr)

-35.07%

Earnings Growth (Qtr)

-400.64%

Breaking Down ALPN Revenue

Last 7 days

0.6%

Last 30 days

0.9%

Last 90 days

125.8%

Trailing 12 Months

695.1%

How does ALPN drawdown profile look like?

ALPN Financial Health

Current Ratio

9.56

ALPN Investor Care

Shares Dilution (1Y)

43.01%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	56.5M	0	0	0
2023	25.8M	29.1M	30.8M	58.9M
2022	33.9M	32.0M	31.8M	30.1M
2021	11.4M	18.0M	24.6M	23.4M
2020	2.8M	3.0M	4.6M	9.3M
2019	0	1.1M	1.4M	1.7M
2018	1.5M	1.1M	910.2K	705.0K
2017	2.6M	2.3M	2.0M	1.7M
2016	0	0	1.7M	3.0M
2015	0	0	0	492.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alpine Immune Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	rickey james paul	acquired	161,629	6.03973	26,761	see remarks
Apr 25, 2024	topper james n	sold	-1,226	64.57	-19.00	-
Apr 25, 2024	topper james n	acquired	1,200	0.001	1,200,000	-
Jan 26, 2024	rickey james paul	acquired	977,844	8.30342	117,764	see remarks
Jan 26, 2024	rickey james paul	sold	-2,745,830	23.3164	-117,764	see remarks
Jan 25, 2024	rickey james paul	sold	-5,192	22.00	-236	see remarks
Jan 25, 2024	rickey james paul	acquired	1,536	6.51	236	see remarks
Jan 18, 2024	decheng capital china life sciences usd fund iii, l.p.	acquired	15,729,300	12.74	1,234,640	-
Jan 18, 2024	cui xiangmin	acquired	15,729,300	12.74	1,234,640	-
Jan 11, 2024	orbimed advisors llc	acquired	1,850,500	12.74	145,251	-

Which funds bought or sold ALPN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CREDIT SUISSE AG/	added	20.44	767,103	1,276,840	-%
May 10, 2024	CITIGROUP INC	added	479	7,543,230	8,225,140	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-18.00	3,143,800	7,602,120	-%
May 10, 2024	Covestor Ltd	new	-	-	-	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-10.93	537,365	1,167,760	-%
May 10, 2024	BlackRock Inc.	added	16.89	83,421,700	141,717,000	-%
May 10, 2024	AJOVista, LLC	sold off	-100	-64,251	-	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	new	-	238	238	-%
May 10, 2024	PNC Financial Services Group, Inc.	new	-	2,141	2,141	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	5.34	14,026	25,805	-%

Are Funds Buying or Selling ALPN?

Are funds buying ALPN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALPN

No. of Funds

Unveiling Alpine Immune Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 30, 2024	decheng capital china life sciences usd fund iii, l.p.	10.0%	6,582,380	SC 13D/A
Apr 29, 2024	frazier life sciences viii, l.p.	4.3%	2,829,347	SC 13D/A
Mar 07, 2024	blackrock inc.	4.6%	3,026,330	SC 13G/A
Feb 14, 2024	omega fund vi, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	paradigm biocapital advisors lp	5.5%	3,176,743	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.6%	3,813,926	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	4.39%	2,550,000	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	5,903,234	SC 13G/A
Feb 14, 2024	great point partners llc	6.37%	3,703,433	SC 13G/A
Feb 02, 2024	blackrock inc.	5.3%	3,058,498	SC 13G

Recent SEC filings of Alpine Immune Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	SC 14D9/A	SC 14D9/A
May 10, 2024	SC TO-T/A	SC TO-T/A
May 09, 2024	8-K	Current Report
May 09, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	SC TO-T/A	SC TO-T/A

Peers (Alternatives to Alpine Immune Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Alpine Immune Sciences Inc News

Latest updates

Alpine Immune Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-77.2%	7,032,000	30,853,000	10,043,000	8,593,000	9,387,000	2,776,000	8,367,000	5,292,000	13,629,000	4,530,000	8,516,000	7,193,000	3,204,000	5,643,000	1,913,000	688,000	1,091,000	884,000	289,000	567,000	448,000
Operating Expenses	1.4%	29,728,000	29,306,000	24,593,000	24,248,000	24,979,000	23,145,000	22,199,000	21,781,000	21,086,000	19,906,000	21,779,000	17,924,000	13,693,000	12,104,000	8,884,000	10,440,000	6,656,000	7,901,000	11,999,000	12,719,000	11,445,000
S&GA Expenses	-100.0%	-	6,374,000	5,443,000	5,007,000	5,398,000	4,389,000	4,610,000	4,194,000	4,775,000	4,544,000	3,470,000	3,290,000	3,256,000	3,049,000	2,728,000	3,344,000	1,778,000	2,102,000	2,467,000	2,553,000	2,514,000
R&D Expenses	-2.1%	22,457,000	22,932,000	19,150,000	19,241,000	19,581,000	18,756,000	17,589,000	17,587,000	16,311,000	15,362,000	18,309,000	14,634,000	10,437,000	9,055,000	6,156,000	7,096,000	4,878,000	5,799,000	9,532,000	10,166,000	8,931,000
EBITDA Margin	-4.4%	-0.56	-0.53	-1.81	-1.96	-2.33	-1.81	-1.62	-1.61	-1.36	-2.09	-1.62	-1.81	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	28,000	70,000	87,000	105,000	130,000	154,000	178,000	203,000	218,000	217,000	215,000	214,000	226,000	120,000	141,000	66,000	61,000	76,000
Income Taxes	-100.0%	-	103,000	-	-	-	548,000	-	1,778,000	4,000	-298,000	80,000	131,000	-	-	-	-6,000	-	-	-	-	-61,000
Earnings Before Taxes	-100.0%	-	6,063,000	-11,722,000	-13,156,000	-13,266,000	-18,316,000	-13,273,000	-16,320,000	-7,523,000	-15,465,000	-13,414,000	-10,898,000	-10,643,000	-6,342,000	-6,137,000	-9,934,000	-	-6,140,000	-11,475,000	-11,856,000	-11,196,000
EBT Margin	-4.2%	-0.57	-0.54	-1.83	-1.99	-2.37	-1.84	-1.65	-1.65	-1.40	-2.15	-1.68	-1.89	-	-	-	-	-	-	-	-	-
Net Income	-400.6%	-17,918,000	5,960,000	-11,722,000	-13,156,000	-13,266,000	-18,864,000	-13,273,000	-18,098,000	-7,527,000	-15,167,000	-13,494,000	-11,029,000	-10,643,000	-6,342,000	-6,137,000	-9,928,000	-5,533,000	-6,140,000	-11,475,000	-11,856,000	-11,135,000
Net Income Margin	-19.2%	-0.65	-0.55	-1.85	-2.01	-2.46	-1.92	-1.70	-1.70	-1.39	-2.15	-1.69	-1.90	-	-	-	-	-	-	-	-	-
Free Cashflow	-45.2%	-27,709,000	-19,085,000	-15,799,000	-18,370,000	-26,245,000	-16,902,000	-16,403,000	-16,284,000	5,423,000	-14,778,000	30,134,000	-14,712,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.6%	374	380	241	253	262	287	292	216	234	256	233	160	130	144	154	103	50.00	54.00	65.00	70.00	67.00
Current Assets	-6.6%	308	330	197	207	199	241	253	172	176	192	184	140	100	107	143	91.00	38.00	42.00	52.00	57.00	65.00
Cash Equivalents	-24.2%	33.00	44.00	19.00	34.00	14.00	13.00	127	25.00	35.00	68.00	76.00	19.00	13.00	35.00	141	88.00	25.00	17.00	18.00	16.00	42.00
Net PPE	-8.6%	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
Liabilities	-21.1%	41.00	52.00	79.00	83.00	93.00	107	110	116	119	135	111	116	77.00	82.00	87.00	86.00	25.00	25.00	30.00	25.00	11.00
Current Liabilities	-23.2%	32.00	42.00	52.00	53.00	57.00	58.00	68.00	63.00	68.00	70.00	64.00	60.00	43.00	41.00	36.00	28.00	5.00	9.00	14.00	13.00	9.00
Long Term Debt	-	-	-	-	-	-	-	-	1.00	2.00	3.00	5.00	6.00	6.00	8.00	9.00	10.00	8.00	5.00	5.00	1.00	2.00
LT Debt, Current	-	-	-	-	-	2.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	3.00	1.00	0.00	2.00	0.00	-	2.00	2.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	1.00	2.00	3.00	5.00	6.00	6.00	8.00	9.00	10.00	8.00	5.00	5.00	1.00	2.00
Shareholder's Equity	1.5%	333	328	162	169	170	179	182	100	115	121	123	44.00	53.00	62.00	67.00	16.00	25.00	29.00	35.00	45.00	57.00
Retained Earnings	-7.0%	-274	-256	-262	-250	-237	-223	-205	-191	-173	-166	-151	-137	-126	-115	-109	-103	-93.46	-87.93	-81.79	-70.31	-58.45
Additional Paid-In Capital	4.0%	607	584	424	420	407	404	389	293	290	287	274	181	180	178	177	120	118	117	117	116	115
Shares Outstanding	8.6%	66.00	60.00	49.00	49.00	48.00	46.00	32.00	30.00	30.00	25.00	25.00	24.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	349	-	-	-	132	-	-	-	105	-	-	-	50.00	-	-	-	21.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-46.0%	-27,690	-18,971	-15,798	-18,091	-26,152	-16,786	-16,348	-16,069	5,449	-14,729	30,134	-14,682	-15,971	-9,349	-5,392	54,519	-9,694	-5,671	-10,575	-7,877	-11,223
Share Based Compensation	42.3%	3,989	2,803	2,654	2,621	2,552	2,469	2,555	2,335	2,289	1,460	1,638	1,545	1,597	949	973	1,232	986	780	825	682	754
Cashflow From Investing	97.7%	-2,562	-112,702	-535	29,328	28,350	-107,899	25,790	6,564	-37,803	-4,285	-62,515	20,866	-6,546	-96,849	1,843	9,057	13,130	4,388	10,863	-17,587	19,099
Cashflow From Financing	-87.6%	19,351	156,610	1,201	8,398	-1,087	11,543	92,816	-1,020	-650	10,873	89,680	9.00	202	-11.00	56,390	2.00	5,000	-	1,646	-509	23,118

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALPN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration [Member]	Collaboration [Member]
Collaboration revenue	$ 7,032	$ 9,387
Operating expenses:
Research and development	22,457	19,581
General and administrative	7,271	5,398
Total operating expenses	29,728	24,979
Loss from operations	(22,696)	(15,592)
Other income (expense):
Interest income	4,781	2,418
Interest expense	0	(70)
Other, net	(3)	(22)
Net loss	(17,918)	(13,266)
Comprehensive income (loss):
Unrealized (loss) gain on investments	(551)	745
Unrealized loss on foreign currency translation	(109)	(31)
Comprehensive loss	$ (18,578)	$ (12,552)
Weighted-average shares used to compute basic net loss per share (in shares)	64,033,018	47,568,149
Weighted-average shares used to compute diluted net loss per share (in shares)	64,033,018	47,568,149
Basic net loss per share (in dollars per share)	$ (0.28)	$ (0.28)
Diluted net loss per share (in dollars per share)	$ (0.28)	$ (0.28)

ALPN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 33,015	$ 43,921
Short-term investments	272,646	283,491
Accounts receivable	42	167
Prepaid expenses and other current assets	2,548	2,455
Total current assets	308,251	330,034
Restricted cash, noncurrent	269	268
Property and equipment, net	1,356	1,484
Operating lease, right-of-use asset	7,317	7,510
Long-term investments	56,453	40,556
Total assets	373,646	379,852
Current liabilities:
Accounts payable	4,170	3,593
Accrued liabilities	16,891	21,187
Deferred revenue, current	10,227	16,288
Operating lease liability, current	950	912
Total current liabilities	32,238	41,980
Deferred revenue, noncurrent	0	929
Operating lease liability, noncurrent	8,705	9,002
Total liabilities	40,943	51,911
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value per share; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 65,552,322 and 60,347,457 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	66	60
Additional paid-in capital	606,963	583,629
Accumulated other comprehensive (loss) income	(263)	397
Accumulated deficit	(274,063)	(256,145)
Total stockholders’ equity	332,703	327,941
Total liabilities and stockholders’ equity	$ 373,646	$ 379,852

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

CEO	Dr. Mitchell H. Gold M.D.
WEBSITE	alpineimmunesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	126

Alpine Immune Sciences Inc Frequently Asked Questions

What is the ticker symbol for Alpine Immune Sciences Inc? What does ALPN stand for in stocks?

ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alpine Immune Sciences Inc (ALPN)?

As of Mon May 13 2024, market cap of Alpine Immune Sciences Inc is 4.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers. The fair value of Alpine Immune Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alpine Immune Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alpine Immune Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALPN is over valued or under valued. Whether Alpine Immune Sciences Inc is cheap or expensive depends on the assumptions which impact Alpine Immune Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALPN.

What is Alpine Immune Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ALPN's PE ratio (Price to Earnings) is -120.97 and Price to Sales (PS) ratio is 78.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALPN PE ratio will change depending on the future growth rate expectations of investors.